Organon & Co. (trading under the ticker OGN) has experienced notable upward momentum and strong performance driven by value-oriented investor interest, positive developments in its specialty pharmaceutical and women's health pipelines (such as regulatory and commercial progress for products like the Miudella IUD and VTAMA cream), and broader market perception that the equity has traded at an attractive valuation relative to its historical multiples and upcoming cash flow conversion potential.